Share this article
VIRGINIA BEACH, Va., Dec. 29, 2020 /PRNewswire/ ViviGen
® Cellular Bone Matrix the first cellular allograft to recover and protect viable, lineage-committed bone cells supports outcomes that are comparable to autograft and superior to a conventional mesenchymal stem cell (MSC)-based cellular allograft in even high-risk foot and ankle procedures, according to two recent peer-reviewed publications.
Foot & Ankle Specialist showed that ViviGen supports fusion even in patients with comorbidities that create higher risk of nonunion, such as diabetes, thyroid disease and alcohol abuse. The overall fusion rate across two high-risk patient groups 113 undergoing arthrodesis and 22 undergoing open reduction internal fixation (ORIF) was 86 percent, which is comparable to fusion procedures using autograft while avoiding the challenges associated with autograft recovery. There also was no statistical difference in the fusion rate between primary and revision pro